Alvón Pharma projects 800M riyals from Terzibatide
Avilon Pharma announced the signing of an exclusive licensing agreement with One Source for Specialized Medicines to register and market the drug Tirzepatide in Saudi Arabia and several countries in the Middle East and North Africa region. The goal is to achieve cumulative revenues of no less than 800 million SAR during the first five years of its launch. The drug is used to treat diabetes and metabolic diseases and is part of the company's strategy to strengthen its pharmaceutical portfolio and expand its regional presence. The agreement duration is 10 years, with renewal options after the launch. The launch timetable depends on the expiration of patents in the targeted markets.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)